Work

Proteomics-based Investigation of Substrates for the Leishmania mexicana Deubiquitinase DUB2

Year: 2023
Type: dissertation
Abstract: Leishmaniasis is a neglected tropical vector-borne disease and is caused by the protozoan parasite Leishmania.Leishmania has a complex digenetic life cycle, and the cellular differentiation that occurs during differentiation is orchestrated in part by the ubiquitin-proteasome pathway, including the ubiquitin-cleaving deubiquitinase (DUB) cysteine peptidases.The parasite expresses 20 DUBs, and four of them are essential for the viability of the insect-stage promastigote form of the parasite.Inducible gene deletion also identifies DUB2 as being important in establishing infection in mice, therefore reflecting a potential drug target.However, the function of DUB2 is not clear.Thus, we aimed to identify the substrates of DUB2 using two approaches.Firstly, using affinity-based ubiquitinated peptide enrichment (ubiquitinomics), 113 proteins were identified that had an increased ubiquitin level upon inducible deletion of DUB2.Secondly, proximity dependent biotinylation (interactomics) revealed 73 proteins that were significantly enriched and therefore in close proximity to DUB2.Gene ontology enrichment analysis categorised these proteins in various biological processes, with transporting and translation top for the ubiquitinomics and interactomics datasets, respectively.DUB2 appears therefore to have a pleiotropic function.Overlapping hits, including UBC2 and SUMO, have been classified as promising DUB2 substrates, and validation is in progress.In the same study, we also conducted a drug screening campaign in collaboration with Novartis (Fast lab), in which 50,000 compounds were tested against the recombinantly expressed LmDUB2.From this initial screen, 438 compounds inhibited Leishmania mexicana DUB2 proteolytic activity, with a followed-up dose response experiment categorizing 86 of these compounds as high/moderate inhibitors (IC50 < 10 μM).Subsequently, in further collaboration with Novartis, we are actively investigating an additional screening strategy involving chemically related compounds.This effort is aimed at expanding the pool of potential selective and promising compounds against and LmDUB2.
Institution: University of York
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7024210726
Cites: 469
Cited by: 1
Related to: 9